Pharmacokinetics of dexmedetomidine during analgosedation in ICU patients
Open Access
- 30 December 2017
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 45 (2) , 277-284
Abstract
Dexmedetomidine (DEX) is a fairly new alfa2-agonist which has been increasingly used in recent years for analgosedation, mostly because it offers a unique ability of providing both moderate level of sedation and analgesia without respiratory depression. Despite of many papers published, there are still only a few concerning the PK of the drug given as long-term infusion in ICU patients. The aim of this work was to characterize the population pharmacokinetics of dexmedetomidine and to investigate the potential benefits of individualization of drug dosing based on patient characteristics in the heterogeneous group of medical and surgical patients staying in intensive care unit. This study was performed in the group of 17 males and 10 females patients with a median age of 59.5 years and median body weight of 75 kg. Blood samples for dexmedetomidine assay were collected from arterial catheter, during and after discontinuation of a standard infusion, that ranged from 24 to 102 h. The following covariates were examined to influence dexmedetomidine PK: age, sex, body weight, patients’ health status described by Sequential Organ Failure Assessment Score (SOFA), inotropes usage, and infusion duration. The dexmedetomidine PK was best described by a two-compartment model. The typical values of PK parameters were estimated as 27 L for the volume of the central compartment, 87.6 L for the volume of the peripheral compartment, 38.5 L/h (9.2 mL/min/kg for a 70 kg patient) for systemic clearance and 46.4 L/h for the distribution clearance. Those values are consistent with literature findings. We were unable to show any significant relationship between collected covariates and dexmedetomidine PK. This study does not provide sufficient evidence to support the individualization of dexmedetomidine dosing based on age, sex, body weight, SOFA, and infusion duration.Keywords
Funding Information
- Kosciuszko Foundation
- Polish National Science Centre (2015/17/B/NZ7/03032)
This publication has 34 references indexed in Scilit:
- Population Pharmacokinetics of Dexmedetomidine in Critically Ill PatientsClinical Drug Investigation, 2013
- Dexmedetomidine: An adjuvant making large inroads into clinical practiceAnnals of Medical and Health Sciences Research, 2013
- Pharmacokinetics of prolonged infusion of high-dose dexmedetomidine in critically ill patientsCritical Care, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patientsActa Anaesthesiologica Scandinavica, 2011
- Highly variable pharmacokinetics of dexmedetomidine during intensive care: a case reportJournal of Medical Case Reports, 2010
- Dexmedetomidine pharmacokinetics in pediatric intensive care – a pooled analysisPediatric Anesthesia, 2009
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- Extensions to the Visual Predictive Check to facilitate model performance evaluationJournal of Pharmacokinetics and Pharmacodynamics, 2008
- Bioavailability of dexmedetomidine after extravascular doses in healthy subjectsBritish Journal of Clinical Pharmacology, 2003